Peer-Review Report of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (5339)
All Articles published online
|
Publishing Process of This Article
|
Jan 6, 2024 (publication date) through Apr 5, 2026
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Clinical Cases
ISSN
2307-8960
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| Liu K, Li ZH. Efficacy and safety of Nafamostat mesylate in patients with end-stage renal failure. World J Clin Cases 2024; 12(1): 68-75 [PMID: 38292627 DOI: 10.12998/wjcc.v12.i1.68] |
|
|
|
| ©2004-2026 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA | |
| For: | Liu K, Li ZH. Efficacy and safety of Nafamostat mesylate in patients with end-stage renal failure. World J Clin Cases 2024; 12(1): 68-75 [PMID: 38292627 DOI: 10.12998/wjcc.v12.i1.68] |
|---|---|
| URL: | https://www.wjgnet.com/2307-8960/full/v12/i1/68.htm |
| Number | Citing Articles |
| 1 |
Pei Xie, Huijun Liu, Xingli Huo, Junlong Chen, Yu Li, Yu Huang, Zongning Yin. Nafamostat Mesylate Regulates Glycosylation to Alleviate Aristolochic Acid Induced Kidney Injury. Toxins 2025; 17(3): 145 doi: 10.3390/toxins17030145
|
| 2 |
Caihong Liu, Yingying Yang, Jinglei Ren, Yongxiu Huang, Wei Wei, Xu Li, Fang Wang, Xue Tang, Ping Fu, Ling Zhang, Yuliang Zhao. Nafamostat mesilate as anticoagulant for blood purification: a systematic review and meta-analysis. Critical Care 2025; 30(1) doi: 10.1186/s13054-025-05813-w
|
| 3 |
Yao Wang, Qiuhong He, Dan Wen, Rong Xu, Xiao Yu, Lingning Zhao. Efficacy and safety of nafamostat mesylate versus heparin anticoagulation in adult kidney disease patients using continuous renal replacement therapy: a systematic review and meta-analysis. Frontiers in Medicine 2026; 13 doi: 10.3389/fmed.2026.1713412
|
| 4 |
Lili Jiang, Jiaoyan Chen, Jurong Yang, Yan Sun, Mingyue Hou, Yunyan Wang. Increasing the Time Interval Suppresses Adverse Effects After Concomitant Use of Nafamostat Mesylate and Levocarnitine in Dialysis Patients: Case Series. Clinical Therapeutics 2025; 47(11): 1080 doi: 10.1016/j.clinthera.2025.08.014
|
| 5 |
Wei Wang, Jiagui Zhao, Xuechao Zhang, Le Wang, Xinyue Zhang, Zonghao Zhang, Shuyuan Qian. Comparison of Anticoagulant Effects of Nafamostat Mesilate and Heparin in Continuous Renal Replacement Therapy for Patients with High Bleeding Risk: A Meta-Analysis Systemic Review. Kidney Diseases 2026; 12(1): 302 doi: 10.1159/000550804
|
| 6 |
Shin Yeong Lee, Jin Sug Kim, Hwa Jeong Kim, Jeong Min Yoon, Moon Jeong Seo, Ji Yung Lee, Kyung-A Choi, Kyun Sang Lee, Ah Ran Choi, Sung Min Ko, Kyoung Hwa Seo, Hae Rim Kim. Development of a predictive model for nafamostat mesylate dosing in hemodialysis. BMC Nephrology 2025; 26(1) doi: 10.1186/s12882-025-04520-6
|
| 7 |
Mengai Miao, Zhile Chen. Impact of Nafamostat Mesylate Combined with Continuous Renal Replacement Therapy on Clinical Outcomes, Immune Function, and Oxidative Stress Markers in Patients with Sepsis-Associated Acute Kidney Injury. British Journal of Hospital Medicine 2025; 86(2): 1 doi: 10.12968/hmed.2024.0615
|